Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
13
pubmed:dateCreated
2011-7-7
pubmed:abstractText
Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree of pharmacophore homology between these two targets was discovered. This similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1520-4804
pubmed:author
pubmed-author:AtadjaPeterP, pubmed-author:CaoXueyingX, pubmed-author:ChenChristine HCH, pubmed-author:ChoYoung ShinYS, pubmed-author:DavisNicole RNR, pubmed-author:EckmanJoeJ, pubmed-author:FanJianmeiJ, pubmed-author:FeketeAlexA, pubmed-author:FirestoneBrantB, pubmed-author:FlynnJulieJ, pubmed-author:GreenJackJ, pubmed-author:GrowneyJoseph DJD, pubmed-author:HolmqvistMatsM, pubmed-author:HsuMeierM, pubmed-author:JanssonDanielD, pubmed-author:JiangLeiL, pubmed-author:KwonPaulP, pubmed-author:LiuGangG, pubmed-author:LombardoFrancoF, pubmed-author:LuQiangQ, pubmed-author:MajumdarDyutiD, pubmed-author:PerezLawrenceL, pubmed-author:PuMinyingM, pubmed-author:RamseyTimT, pubmed-author:RemiszewskiStacyS, pubmed-author:ShultzMichael DMD, pubmed-author:SkolnikSuzanneS, pubmed-author:StecherThomasT, pubmed-author:TraebertMartinM, pubmed-author:UrbanLaszloL, pubmed-author:UttamsinghVinitaV, pubmed-author:WangPingP, pubmed-author:WhitebreadStevenS, pubmed-author:WhiteheadLewisL, pubmed-author:Yan-NealeYanY, pubmed-author:YaoYung-MaeYM, pubmed-author:ZhouLipingL
pubmed:issnType
Electronic
pubmed:day
14
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4752-72
pubmed:meshHeading
pubmed-meshheading:21650221-Acrylamides, pubmed-meshheading:21650221-Animals, pubmed-meshheading:21650221-Antineoplastic Agents, pubmed-meshheading:21650221-Drug Screening Assays, Antitumor, pubmed-meshheading:21650221-Ether-A-Go-Go Potassium Channels, pubmed-meshheading:21650221-HCT116 Cells, pubmed-meshheading:21650221-Half-Life, pubmed-meshheading:21650221-Histone Deacetylase Inhibitors, pubmed-meshheading:21650221-Humans, pubmed-meshheading:21650221-Hydroxamic Acids, pubmed-meshheading:21650221-Mice, pubmed-meshheading:21650221-Mice, Nude, pubmed-meshheading:21650221-Microsomes, Liver, pubmed-meshheading:21650221-Models, Molecular, pubmed-meshheading:21650221-Neoplasm Transplantation, pubmed-meshheading:21650221-Patch-Clamp Techniques, pubmed-meshheading:21650221-Radioligand Assay, pubmed-meshheading:21650221-Rats, pubmed-meshheading:21650221-Rats, Sprague-Dawley, pubmed-meshheading:21650221-Stereoisomerism, pubmed-meshheading:21650221-Structure-Activity Relationship, pubmed-meshheading:21650221-Tissue Distribution, pubmed-meshheading:21650221-Transplantation, Heterologous
pubmed:year
2011
pubmed:articleTitle
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
pubmed:affiliation
Novartis Institutes for Biomedical Research, Inc., Cambridge, Massachusetts 02139, United States. michael.shultz@novartis.com
pubmed:publicationType
Journal Article, In Vitro